CHAOSTOCOSMOS

Thursday, 2 July 2015

Fluge & Mella’s pre-trial study highlights life-changing potential of rituximab

Dr Øystein Fluge and Professor Olav Mella have published their new study in PLoS ONE. And though the study was not a blinded, placebo-controlled trial, the results are further evidence that rituximab is beneficial in some ME/CFS patients, and potentially life-changing for a substantial minority. The findings also give important new insights into the optimum dosing schedule to maintain those benefits in the long run.



Fluge & Mella’s pre-trial study highlights life-changing potential of rituximab

No comments:

Related Posts Plugin for WordPress, Blogger...
^ Top